Tandemly repeated Fc domain augments binding avidities of antibodies for Fcγ receptors, resulting in enhanced antibody-dependent cellular cytotoxicity

Molecular Immunology

Volumn 45, Issue 10, 2008, Pages 2752-2763

  Nagashima, Hiroaki ^a   Tezuka, Tomoya ^a   Tsuchida, Wakako ^a   Maeda, Hiroaki ^b   Kohroki, Junya ^a   Masuho, Yasuhiko ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Antibody dependent cellular cytotoxicity (ADCC); CD20; Fc tandem repeat antibodies; Fc receptors; Linker

Indexed keywords

CD20 ANTIBODY; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IIIA; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; TANDEM REPEAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA, COMPLEMENTARY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MICE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IGG; REPETITIVE SEQUENCES, AMINO ACID;

EID: 41849090725     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.02.003     Document Type: Article

References (37)

1. Bowles J.A., Wang S.Y., Link B.K., Allan B., Beuerlein G., Campbell M.A., Marquis D., Ondek B., Wooldridge J.E., Smith B.J., Breitmeyer J.B., and Weiner G.J. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108 (2006) 2648-2654
2. Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M., Lucas D., and Reed J.C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
3. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., and Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99 (2002) 754-758
4. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., and Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346 (2002) 235-242
5. Cragg M.S., Morgan S.M., Chan H.T., Morgan B.P., Filatov A.V., Johnson P.W., French R.R., and Glennie M.J. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101 (2003) 1045-1052
6. Cragg M.S., and Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103 (2004) 2738-2743
7. Dall'Acqua W.F., Cook K.E., Damschroder M.M., Woods R.M., and Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 177 (2006) 1129-1138
8. Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., Botto M., Introna M., and Golay J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171 (2003) 1581-1587
9. Eerola A.K., Soini Y., and Pääkkö P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin. Cancer Res. 6 (2000) 1875-1881
10. Ernst L.K., Metes D., Herberman R.B., and Morel P.A. Allelic polymorphisms in the FcγRIIC gene can influence its function on normal human natural killer cells. J. Mol. Med. 80 (2002) 248-257
11. Ginaldi L., De Martinis M., Matutes E., Farahat N., Morilla R., and Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J. Clin. Pathol. 51 (1998) 364-369
12. Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E.G.Kr., and de Haas M. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 90 (1997) 1109-1114
13. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., and Dahiyat B.I. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 4005-4010
14. Maenaka K., van der Merwe P.A., Stuart D.I., Jones E.Y., and Sondermann P. The human low affinity Fcgγ receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J. Biol. Chem. 276 (2001) 44898-44904
15. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., Sotto J.J., Leroux D., Bensa J.C., and Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101 (2003) 949-954
16. McCall A.M., Shahied L., Amoroso A.R., Horak E.M., Simmons H.H., Nielson U., Adams G.P., Schier R., Marks J.D., and Weiner L.M. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J. Immunol. 166 (2001) 6112-6117
17. Megeed Z., Winters R.M., and Yarmush M.L. Modulation of single-chain antibody affinity with temperature-responsive elastin-like polypeptide linkers. Biomacromolecules 7 (2006) 999-1004
18. Nielsen S.U., and Routledge E.G. Human T cells resistant to complement lysis by bivalent antibody can be efficiently lysed by dimers of monovalent antibody. Blood 100 December 1 (12) (2002) 4067-4073
19. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
20. Nimmerjahn F., and Ravetch J.V. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19 (2007) 239-245
21. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
22. Perosa F., Favoino E., Caragnano M.A., and Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 107 (2006) 1070-1077
23. Preithner S., Elm S., Lippold S., et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol. Immunol. 43 (2006) 1183-1193
24. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., and Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
25. Reichert J.M., Rosensweig C.J., Faden L.B., and Dewitz M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23 (2005) 1073-1078
26. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the Fcγ R. J. Biol. Chem. 276 (2001) 6591-6604
27. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., and Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002) 26733-26740
28. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., and Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
29. Sondermann P., Huber R., Oosthuizen V., and Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 406 (2000) 267-273
30. Stanford M.M., and Issekutz T.B. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo. J. Leukocyte Biol. 74 (2003) 791-799
31. Takai T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2 (2002) 580-592
32. Tang Y., Lou J., Alpaugh R.K., Robinson M.K., Marks J.D., and Weiner L.M. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J. Immunol. 179 (2007) 2815-2823
33. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., Valerius T., van de Winkel J.G., and Glennie M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 (2004) 1793-1800
34. van Meerten T., van Rijn R.S., Hol S., Hagenbeek A., and Ebeling S.B. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12 (2006) 4027-4035
35. van Oers M.H., Klasa R., Marcus R.E., Wolf M., Kimby E., Gascoyne R.D., Jack A., Van't Veer M., Vranovsky A., Holte H., van Glabbeke M., Teodorovic I., Rozewicz C., and Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108 (2006) 3295-3301
36. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (2003) 3940-3947
37. Wolff E.A., Schreiber G.J., Cosand W.L., and Raff H.W. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res. 53 (1993) 2560-2565